Great Basin Begins Clinical Trial for C. Difficile Test on Automated MDx Platform
June 30, 2011
Great Basin Begins Clinical Trial for C. Difficile Test on Automated MDx Platform
The company said that it has achieved encouraging results in a preclinical study of the assay, and that if clinical trial results are equally positive it will submit the test for US Food and Drug Administration approval by the end of the summer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Great Basin Moving POC MDx Platform to Market; Eyes Summer Clinical Trials for First Two Tests
February 17, 2011 / PCR Insider - Quidel Obtains CE Mark for AmpliVue C. Difficile, Company's First Handheld MDx Test
March 29, 2012 / PCR Insider - Study Shows Great Basin C. diff Test Sensitive, Specific as Established Real-Time PCR Assay
August 16, 2012 / PCR Insider - BD Diagnostics Execs Update Molecular Pipeline; New Tests for BD MAX and Viper on Horizon
August 9, 2012 / PCR Insider - Great Basin Names European, NZ Distributors for First MDx Test
July 11, 2012 / PCR Insider